Literature DB >> 25211648

Ventilatory chemosensitivity, cerebral and muscle oxygenation, and total hemoglobin mass before and after a 72-day mt. Everest expedition.

Stephen S Cheung1, Niina E Mutanen, Heikki M Karinen, Anne S Koponen, Heikki Kyröläinen, Heikki O Tikkanen, Juha E Peltonen.   

Abstract

BACKGROUND: We investigated the effects of chronic hypobaric hypoxic acclimatization, performed over the course of a 72-day self-supported Everest expedition, on ventilatory chemosensitivity, arterial saturation, and tissue oxygenation adaptation along with total hemoglobin mass (tHb-mass) in nine experienced climbers (age 37±6 years, [Formula: see text] 55±7 mL·kg(-1)·min(-1)).
METHODS: Exercise-hypoxia tolerance was tested using a constant treadmill exercise of 5.5 km·h(-1) at 3.8% grade (mimicking exertion at altitude) with 3-min steps of progressive normobaric poikilocapnic hypoxia. Breath-by-breath ventilatory responses, Spo2, and cerebral (frontal cortex) and active muscle (vastus lateralis) oxygenation were measured throughout. Acute hypoxic ventilatory response (AHVR) was determined by linear regression slope of ventilation vs. Spo2. PRE and POST (<15 days) expedition, tHb-mass was measured using carbon monoxide-rebreathing.
RESULTS: Post-expedition, exercise-hypoxia tolerance improved (11:32±3:57 to 16:30±2:09 min, p<0.01). AHVR was elevated (1.25±0.33 to 1.63±0.38 L·min(-1.)%(-1) Spo2, p<0.05). Spo2 decreased throughout exercise-hypoxia in both trials, but was preserved at higher values at 4800 m post-expedition. Cerebral oxygenation decreased progressively with increasing exercise-hypoxia in both trials, with a lower level of deoxyhemoglobin POST at 2400, 3500 and 4800 m. Muscle oxygenation also decreased throughout exercise-hypoxia, with similar patterns PRE and POST. No relationship was observed between the slope of AHVR and cerebral or muscle oxygenation either PRE or POST. Absolute tHb-mass response exhibited great individual variation with a nonsignificant 5.4% increasing trend post-expedition (975±154 g PRE and 1025±124 g POST, p=0.17).
CONCLUSIONS: We conclude that adaptation to chronic hypoxia during a climbing expedition to Mt. Everest will increase hypoxic tolerance, AHVR, and cerebral but not muscle oxygenation, as measured during simulated acute hypoxia at sea level. However, tHb-mass did not increase significantly and improvement in cerebral oxygenation was not associated with the change in AHVR.

Entities:  

Keywords:  NIRS; acute hypoxic ventilatory response; altitude adaptation; chronic hypoxia; climbers; extreme altitude

Mesh:

Substances:

Year:  2014        PMID: 25211648     DOI: 10.1089/ham.2013.1153

Source DB:  PubMed          Journal:  High Alt Med Biol        ISSN: 1527-0297            Impact factor:   1.981


  4 in total

Review 1.  Travelling with heart failure: risk assessment and practical recommendations.

Authors:  Stephan von Haehling; Christoph Birner; Elke Dworatzek; Stefan Frantz; Kristian Hellenkamp; Carsten W Israel; Tibor Kempf; Hermann H Klein; Christoph Knosalla; Ulrich Laufs; Philip Raake; Rolf Wachter; Gerd Hasenfuss
Journal:  Nat Rev Cardiol       Date:  2022-01-06       Impact factor: 49.421

2.  Cardiorespiratory Coordination in Hypercapnic Test Before and After High-Altitude Expedition.

Authors:  Valentina V Gultyaeva; Dmitriy Y Uryumtsev; Margarita I Zinchenko; Vladimir N Melnikov; Natalia V Balioz; Sergey G Krivoschekov
Journal:  Front Physiol       Date:  2021-05-24       Impact factor: 4.566

3.  The influence of short-term high-altitude acclimatization on cerebral and leg tissue oxygenation post-orthostasis.

Authors:  Masahiro Horiuchi; Kazunobu Okazaki; Katsumi Asano; Alexander T Friend; Gabriella M K Rossetti; Samuel J Oliver
Journal:  Eur J Appl Physiol       Date:  2021-07-28       Impact factor: 3.078

4.  Effect of Carbohydrate-Electrolyte Solution Including Bicarbonate Ion Ad Libitum Ingestion on Urine Bicarbonate Retention during Mountain Trekking: A Randomized, Controlled Pilot Study.

Authors:  Masahiro Horiuchi; Tatsuya Hasegawa; Hiroshi Nose
Journal:  Int J Environ Res Public Health       Date:  2021-02-04       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.